Portola Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Portola Pharmaceuticals, Inc. holds 29 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 28 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include ANDEXXA, ONDEXXYA, and PORTOLA PHARMACEUTICALS. The owner is based in South San Francisco, CA.
270 East Grand Avenue
South San Francisco, CA 94080
Showing of trademarks Trademarks
Trademark Classifications
Portola Pharmaceuticals, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Portola Pharmaceuticals, Inc. have?
Portola Pharmaceuticals, Inc. has 29 U.S. trademarks filed with the USPTO. Of these, 4 registered, 22 abandoned, 3 cancelled.
What trademark classes does Portola Pharmaceuticals, Inc. file in?
Portola Pharmaceuticals, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Portola Pharmaceuticals, Inc.'s most well-known trademarks?
Portola Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as ANDEXXA, ONDEXXYA, and PORTOLA PHARMACEUTICALS. These are among 4 currently registered trademarks in the portfolio.
What is Portola Pharmaceuticals, Inc.'s trademark registration success rate?
Portola Pharmaceuticals, Inc. has a 14% trademark registration rate, with 4 out of 29 resolved applications resulting in successful registration. Currently, 0 applications are pending review.